Novel heart disease treatment given $145m boost with Bitterroot Bio funding
Longevity Technology - 19-Jun-2023Biotech leverages insights from immunology and cardiology, aiming to dissolve arterial plaques with their flagship asset, BRB-002
Join the club for FREE to access the whole archive and other member benefits.
Company that leverages the power of immunotherapy to develop and deliver novel medicines for cardiovascular disease
itterroot Bio is committed to pioneering the emerging field of cardio-immunology, which investigates the interplay between the immune system and cardiovascular health. Through our research, we have uncovered the critical roles that immune cells and immune modulators play in the development and progression of cardiovascular disease. Our approach builds on the success of immunotherapies in oncology by harnessing the immune system’s natural ability to fight disease.
By understanding the intricate mechanisms by which these cells contribute to disease, we are developing innovative immunotherapies that target the root causes of cardiovascular disease rather than just treating its symptoms. Our approach is grounded in scientific research and close collaboration with cardiologists to ensure the safety and efficacy of our therapies for patients. Our ultimate goal is to provide new hope to those suffering from cardiovascular disease and transform the way these diseases are treated.
Visit website: https://brbio.com/
Details last updated 22-Jun-2023
Biotech leverages insights from immunology and cardiology, aiming to dissolve arterial plaques with their flagship asset, BRB-002